Description

💊 Dapagliflozin 10mg + Metformin 500mg + Sitagliptin 100mg Tablets

Triple Target Diabetes Care – Enhanced Glycemic Control in One Pill

Overview

Dapagliflozin + Metformin + Sitagliptin is a triple combination oral anti-diabetic medication used to manage Type 2 Diabetes Mellitus in adults. It is prescribed when blood glucose levels are not adequately controlled with monotherapy or dual therapy. This formulation integrates three complementary mechanisms, providing comprehensive and long-lasting blood sugar control.

Drug Class

• Dapagliflozin (10 mg) – SGLT2 Inhibitor
• Metformin (500 mg) – Biguanide
• Sitagliptin (100 mg) – DPP-4 Inhibitor

Mechanism of Action

1. Dapagliflozin: Reduces glucose reabsorption in the kidneys and promotes its excretion through urine, leading to lower blood sugar levels, weight loss, and mild blood pressure reduction.
2. Metformin: Decreases hepatic glucose production, improves insulin sensitivity, and reduces intestinal absorption of glucose.
3. Sitagliptin: Enhances the levels of incretin hormones, which increase insulin secretion and suppress glucagon production after meals, aiding postprandial glucose control.

Together, these three agents provide synergistic effects that cover multiple aspects of glucose regulation.

Indications

• Type 2 Diabetes Mellitus in adults
• Patients with inadequate glycemic control on Metformin + Dapagliflozin, Metformin + Sitagliptin, or dual/triple oral therapy
• To be used in conjunction with diet and exercise

How to Use

• Dosage: As prescribed by the healthcare provider—commonly once or twice daily depending on formulation and blood sugar profile.
• Route: Oral
• Timing: Take with food to minimize gastrointestinal side effects (especially from metformin).
• Swallow the tablet whole with water. Do not crush or chew.

Regular use at the same time each day is recommended for optimal glycemic control.

Benefits

• Triple mechanism for more effective glucose control
• Helps reduce both fasting and post-meal blood sugar
• Promotes weight loss (due to dapagliflozin)
• May reduce the need for insulin in advanced cases
• Supports cardiovascular and renal protection

Side Effects

• Dapagliflozin: Increased urination, genital or urinary tract infections, dehydration
• Metformin: Nausea, diarrhea, abdominal discomfort (especially in the initial weeks)
• Sitagliptin: Headache, upper respiratory symptoms, rare allergic reactions

Rare but serious: Lactic acidosis (from metformin), pancreatitis (rare with sitagliptin), ketoacidosis (from SGLT2 inhibitors)

Precautions

• Not suitable for Type 1 diabetes or diabetic ketoacidosis
• Avoid in patients with moderate to severe kidney dysfunction
• Use with caution in elderly or those on diuretics due to dehydration risk
• Monitor renal function, liver function, and blood glucose levels regularly
• Inform your doctor if you are pregnant, breastfeeding, or undergoing surgery

Storage

• Store at room temperature (below 30°C)
• Keep away from moisture and direct sunlight
• Out of reach of children

When to Contact a Doctor

• Persistent nausea or vomiting
• Signs of low blood sugar (shaking, sweating, confusion)
• Signs of urinary infection or dehydration
• Sudden abdominal pain (possible pancreatitis)

Conclusion

The combination of Dapagliflozin + Metformin + Sitagliptin offers a powerful and convenient once-daily option for managing Type 2 Diabetes. Its triple-action approach targets fasting, postprandial glucose, and insulin sensitivity, making it an ideal therapy for patients requiring intensified treatment.